By Thomas Scharnitz, MD Held as a virtual event this year due to the COVID-19 pandemic, the 29th Congress of the EADV hosted nearly 11,000 attendees logging in from all over the world. Psoriasis played an important role in the EADV agenda, according to conference planners, in recognition that the disease affects 2-3% of the world's population. The EADV virtual congress featured sessions on psoriasis genetics and pathophysiology as well as presentations on promising therapies, from "classical treatments to small molecules," psoriasis and pregnancy, biologics and the treatment of cardiovascular inflammation, and more. The following are summaries of the EADV sessions with a focus on psoriasis.
Latest news Commentary: NPF COVID-19 Task Force Guidance StatementsJanuary 06, 2021Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based. IPC Statement on SARS-CoV-2 Vaccines and PsoriasisDecember 02, 2020While the news of a potential SARS-CoV-2 vaccine is to be welcomed, the impact of psoriasis therapy, particularly systemic therapy, on the effectiveness and safety of vaccines needs to be considered. Psoriasis updates in a nutshell: Pathogenesis, markers and therapeuticsNovember 19, 2020Get the latest updates about psoriasis on topics such as pathogenesis, markers and therapeutics from Dr. Mohamed El-Komy in this short IPC video. Are you a dermatologist practicing in the Middle East?November 03, 2020Get the latest news on treating psoriasis in the Middle East with Dr. El Sayed. More News
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE